QURE vs. VERV

In the year-to-date period, QURE achieves a -18.06% return, which is significantly higher than VERV's -21.10% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for uniQure N.V. (QURE) and Verve Therapeutics, Inc. (VERV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current QURE Sharpe Ratio is 1.21, which is higher than the VERV Sharpe Ratio of -0.14. The chart below compares the historical Sharpe Ratios of QURE and VERV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither QURE nor VERV has paid dividends to shareholders.

The maximum QURE drawdown since its inception was -95.40%, roughly equal to the maximum VERV drawdown of -95.99%. Use the drawdown chart below to compare losses from any high point for QURE and VERV.

uniQure N.V. (QURE) has a higher volatility of 43.95% compared to Verve Therapeutics, Inc. (VERV) at 27.05%. This indicates that QURE's price experiences larger fluctuations and is considered to be riskier than VERV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between uniQure N.V. and Verve Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.